BCL2 and B-cell chronic lymphocytic leukemia: To determine the significance of INPP5F for prognostic and therapeutic decision making, INPP5F cutoff levels need to be defined, and the prognostic relevance of INPP5F expression needs to be analyzed in the context of other therapies used for treatment of CLL such as bendamustine.36, 37 In addition, our data may also support the strategy of combining NF-κB and/or BCL-2 inhibitors to standard therapy in CLL.